# Abrocitinib Treatment of Atopic Dermatitis in Children 2 to Less Than 6 Years of Age

> **NCT07823595** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Pfizer** · enrollment: 90 (estimated)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Abrocitinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07823595
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2027-05-01
- **Primary completion:** 2029-04-10
- **Final completion:** 2029-04-10
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2026-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07823595

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07823595, "Abrocitinib Treatment of Atopic Dermatitis in Children 2 to Less Than 6 Years of Age". Retrieved via MORVS 2026-11-22 from https://api.morvs.ai/clinical/NCT07823595. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*
